Regulatory News
Tuesday, December 13, 2016
BRIEF-Redhill Biopharma says positive DSMB recommendation for continuation of RHB-104 Phase III study
* Redhill Biopharma announces positive and unanimous DSMB
recommendation for continuation of Phase III study with RHB-104
for Crohn's disease
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment